Thompson Siegel & Walmsley LLC Sells 75,498 Shares of IQVIA Holdings Inc. $IQV

Thompson Siegel & Walmsley LLC trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 27.1% during the fourth quarter, HoldingsChannel reports. The fund owned 203,496 shares of the medical research company’s stock after selling 75,498 shares during the quarter. Thompson Siegel & Walmsley LLC’s holdings in IQVIA were worth $45,870,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IQV. Claret Asset Management Corp lifted its holdings in shares of IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after purchasing an additional 49 shares during the period. Leonard Rickey Investment Advisors P.L.L.C. increased its holdings in IQVIA by 3.3% in the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after purchasing an additional 58 shares during the period. Brookstone Capital Management raised its position in IQVIA by 2.2% during the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after purchasing an additional 63 shares during the last quarter. Private Advisor Group LLC lifted its holdings in IQVIA by 1.0% during the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after buying an additional 63 shares during the period. Finally, Keybank National Association OH grew its position in shares of IQVIA by 0.7% in the 4th quarter. Keybank National Association OH now owns 9,103 shares of the medical research company’s stock valued at $2,052,000 after buying an additional 67 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of NYSE IQV opened at $182.03 on Monday. The firm has a market capitalization of $30.38 billion, a P/E ratio of 22.56, a P/E/G ratio of 1.74 and a beta of 1.21. The firm’s 50-day moving average price is $170.34 and its 200-day moving average price is $196.05. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 1-year low of $136.41 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last issued its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. During the same period last year, the business posted $2.70 EPS. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on IQV shares. Truist Financial cut their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Stifel Nicolaus lowered their price target on shares of IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a report on Friday, February 6th. Evercore restated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research report on Wednesday, April 8th. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research report on Friday, February 6th. Finally, Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, April 19th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA has an average rating of “Buy” and an average price target of $225.69.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.